Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Cuad. Hosp. Clín ; 63(2): 17-25, dic. 2022. ilus.
Artigo em Espanhol | LILACS | ID: biblio-1412550

RESUMO

INTRODUCCIÓN: la reciente aparición del COVID-19 implica comprender de los patrones de transmisión, la gravedad, las características clínicas y los factores de riesgo de infección, ya sea entre la población general, entre el personal médico o en el entorno familiar. Los estudios para evaluar las características epidemiológicas y clínicas de los casos en diferentes contextos resultan esenciales para profundizar y comprender mejor este virus y la enfermedad asociada. MATERIAL Y MÉTODOS: el propósito del estudio fue determinar los factores de riesgo relacionados a mortalidad por COVID-19 en pacientes internados en el Hospital de la Portada durante el periodo de la gestión 2020 mediante un estudio transversal analítico. Se incluyó a todos los pacientes internados, desde abril a agosto del 2020, utilizando las fichas epidemiológicas RESULTADOS: las categorías asociadas, fueron el sexo masculino (p = 0,000) duplicando la posibilidad de muerte respecto a las mujeres (OR =2,46) y la eritrocitosis, (p = 0,002), triplicando la posibilidad de muerte respecto a no padecerla (OR = 3,11). La probabilidad de fallecer por COVID 19 con el antecedente de padecer eritrocitosis fue de 55,17%. Los casos de mortalidad más frecuentes fue en población adulta y tercera edad, del sexo masculino. Los antecedentes patológicos más frecuentes fue la hipertensión arterial. Se dejaron de vivir 2179,5 años. La tasa de mortalidad alcanzo a 8,3 muertes por cada 100.000 habitantes. CONCLUSIÓN: es importante considerar el sexo y la eritrocitosis acompañadas de otras patologías de base como factor fundamental, a la mortalidad por COVID 19.


INTRODUCTION: the recent emergence of COVID-19 implies an understanding of transmission patterns, severity, clinical features, and risk factors for infection, whether among the general population, among medical personnel, or in the family setting. Studies to assess the epidemiological and clinical characteristics of cases in different settings are essential to deepen and better understand this virus and the associated disease. MATERIAL AND METHODS: the purpose of the study was to determine the risk factors related to COVID-19 mortality in patients hospitalized at the Hospital de la Portada during the period of the 2020 administration by means of an analytical cross-sectional study. All hospitalized patients were included, from April to August 2020, using epidemiological records. RESULTS: the associated categories were male sex (p = 0.000), doubling the possibility of death with respect to women (OR = 2.46) and erythrocytosis (p = 0.002), tripling the possibility of death with respect to not having it (OR = 3.11). The probability of dying from COVID 19 with a history of erythrocytosis was 55.17%. The most frequent cases of mortality were in the adult and elderly male population. The most frequent pathological history was arterial hypertension. A total of 2179.5 years of life were lost. The mortality rate was 8.3 deaths per 100,000 inhabitants. CONCLUSION: it is important to consider sex and erythrocytosis accompanied by other underlying pathologies as a fundamental factor in mortality due to COVID 19.


Assuntos
Doença , COVID-19 , Estudos Transversais , Mortalidade Hospitalar
2.
Int J Gynaecol Obstet ; 120(1): 65-9, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23073229

RESUMO

OBJECTIVE: To confirm the results of an earlier study assessing the safety and efficacy of a laparoscopic radiofrequency volumetric thermal ablation (RFVTA) system among women with symptomatic myomas. METHODS: In a prospective study at the Hospital of Francisco Marroquin University, Guatemala City, consecutive premenopausal women with symptomatic myomas seeking uterine-sparing treatment were enrolled between August 2008 and July 2011. The women were treated by RFVTA. Uterine fibroid symptom and health-related quality-of-life (UFS-QOL) questionnaires were completed at 0, 3, 6, and 12 months. RESULTS: Among 114 women screened, 36 were enrolled (ages 33-51 years), and 35 were followed for 12 months. Symptom severity scores reduced significantly (P<0.05): baseline (63.3), 3 months (23.1), 6 months (15.4), 12 months (9.6). Health-related quality-of-life scores improved significantly (P<0.05): baseline (37.3), 3 months (79.9), 6 months (85.1), 12 months (87.7). The mean ± SD difference in uterine volume from baseline (215.2 ± 117.9 cm(3)) to 12 months (167.0 ± 120.8 cm(3)) was 48.2 cm(3) (95% CI: -22.8 to 119.2; P=0.192). Nine adverse events among 8 individuals were minor and unrelated to the procedure. CONCLUSION: RFVTA of fibroids resulted in significantly improved symptom severity and quality-of-life scores and provides an outpatient uterine-sparing option for treatment of myomas.


Assuntos
Ablação por Cateter/métodos , Laparoscopia/métodos , Leiomioma/cirurgia , Neoplasias Uterinas/cirurgia , Adulto , Assistência Ambulatorial/métodos , Ablação por Cateter/efeitos adversos , Feminino , Seguimentos , Guatemala , Humanos , Laparoscopia/efeitos adversos , Leiomioma/patologia , Estudos Longitudinais , Pessoa de Meia-Idade , Pré-Menopausa , Estudos Prospectivos , Qualidade de Vida , Índice de Gravidade de Doença , Inquéritos e Questionários , Fatores de Tempo , Neoplasias Uterinas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA